Most patients presented with metastatic disease (epacadostat plus pembrolizumab, 86.4%; placebo plus pembrolizumab, 91.8%), and approximately half had tumors with PD-L1 CPS ≥ 10 (56.8% and 55.1%, respectively) (Table 1). This evidence concerns the gene CD274 and metastatic neoplasm.